FAILED
首站-论文投稿智能助手
典型文献
An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses
文献摘要:
Arthropod-borne chikungunya virus(CHIKV)infection can cause a debilitating arthritic disease in human.However,there are no specific antiviral drugs and effective licensed vaccines against CHIKV available for clinical use.Here,we developed an mRNA-lipid nanoparticle(mRNA-LNP)vaccine expressing CHIKV E2-E1 antigen,and compared its immunogenicity with soluble recombinant protein sE2-El antigen expressed in S2 cells.For com-parison,we first showed that recombinant protein antigens mixed with aluminum adjuvant elicit strong antigen-specific humoral immune response and a moderate cellular immune response in C57BL/6 mice.Moreover,sE2-El vaccine stimulated 12-23 folds more neutralizing antibodies than sE1 vaccine and sE2 vaccine.Significantly,when E2-E1 gene was delivered by an mRNA-LNP vaccine,not only the better magnitude of neutralizing antibody responses was induced,but also greater cellular immune responses were generated,especially for CD8+T cell responses.Moreover,E2-E1-LNP induced CD8+T cells can perform cytotoxic effect in vivo.Considering its better immunogenicity and convenience of preparation,we suggest that more attention should be placed to develop CHIKV E2-E1-LNP mRNA vaccine.
文献关键词:
作者姓名:
Ningning Ge;Jin Sun;Zhihua Liu;Jiayi Shu;Huimin Yan;Zhihua Kou;Yu Wei;Xia Jin
作者机构:
CAS Key Laboratory of Molecular Virology and Immunology,Institut Pasteur of Shanghai,Chinese Academy of Sciences,Shanghai 200031,China;University of Chinese Academy of Sciences,Beijing 100049,China;Shanghai Public Health Clinical Center,Fudan University,Shanghai 200540,China;Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China
文献出处:
引用格式:
[1]Ningning Ge;Jin Sun;Zhihua Liu;Jiayi Shu;Huimin Yan;Zhihua Kou;Yu Wei;Xia Jin-.An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses)[J].中国病毒学,2022(02):266-276
A类:
Arthropod,sE2,sE1
B类:
An,encoding,Chikungunya,virus,protein,elicits,robust,neutralizing,antibody,responses,CTL,immune,borne,chikungunya,CHIKV,infection,cause,debilitating,arthritic,disease,human,However,there,specific,antiviral,drugs,effective,licensed,vaccines,against,available,clinical,Here,developed,lipid,nanoparticle,LNP,expressing,compared,immunogenicity,soluble,recombinant,El,expressed,S2,cells,For,parison,first,showed,that,antigens,mixed,aluminum,adjuvant,strong,humoral,moderate,cellular,C57BL,mice,Moreover,stimulated,folds,more,antibodies,than,Significantly,when,was,delivered,by,not,only,better,magnitude,induced,but,also,greater,were,generated,especially,CD8+T,perform,cytotoxic,vivo,Considering,convenience,preparation,suggest,attention,should,placed
AB值:
0.521388
相似文献
An ultrapotent pan-β-coronavirus lineage B(β-CoV-B)neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Zezhong Liu;Wei Xu;Zhenguo Chen;Wangjun Fu;Wuqiang Zhan;Yidan Gao;Jie Zhou;Yunjiao Zhou;Jianbo Wu;Qian Wang;Xiang Zhang;Aihua Hao;Wei Wu;Qianqian Zhang;Yarning Li;Kaiyue Fan;Ruihong Chen;Qiaochu Jiang;Christian T.Mayer;Till Schoofs;Youhua Xie;Shibo Jiang;Yumei Wen;Zhenghong Yuan;Kang Wang;Lu Lu;Lei Sun;Qiao Wang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Biosecurity;the Fifth People's Hospital of Shanghai;Shanghai Key Laboratory of Medical Epigenetics,International Co-laboratory of Medical Epigenetics and Metabolism(Ministry of Science and Technology);Institutes of Biomedical Sciences;Biosafety Level 3 Laboratory,Shanghai Medical College,Fudan University,Shanghai 200032,China;CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China;Experimental Immunology Branch,Center for Cancer Research,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA;GSK Vaccines,1300 Wavre,Belgium
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice,rabbits and NHPs
Zezhong Liu;Jie Zhou;Wei Xu;Wei Deng;Yanqun Wang;Meiyu Wang;Qian Wang;Ming Hsieh;Jingming Dong;Xinling Wang;Weijin Huangei;Lixiao Xing;Miaoling He;Chunlin Tao;Youhua Xie;Yilong Zhang;Youchun Wang;Jincun Zhao;Zhenghong Yuan;Chuan Qin;Shibo Jiang;Lu Lu-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Blosecurity;Biosafety Level 3 Laboratory,Shanghai Medical College,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Fudan University,Shanghai,China;Key Laboratory of Human Disease Comparative Medicine,National Health Commission of the People's Republic of China;Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases,Institute of Laboratory Animal Science,Chinese Academy of Medical Sciences and Comparative Medicine Center,Peking Union Medical College,Beijing,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Guangzhou Laboratory,Bio-Island,Guangzhou,China;Graduate School of Peking Union Medical College,No.9 Dongdan Santiao,Dongcheng District,Beijing,China;Division of HIV/AIDS and Sex-transmitted Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control(NIFDC),No.31 Huatuo Street,Daxing District,Beijing,China;Fulgent Pharma LLC.,4978 Santa Anita Avenue,Temple City,CA,USA
Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
Yong-Qiang Deng;Na-Na Zhang;Yi-Fei Zhang;Xia Zhong;Sue Xu;Hong-Ying Qiu;Tie-Cheng Wang;Hui Zhao;Chao Zhou;Shu-Long Zu;Qi Chen;Tian-Shu Cao;Qing Ye;Hang Chi;Xiang-Hui Duan;Dan-Dan Lin;Xiao-Jing Zhang;Liang-Zhi Xie;Yu-Wei Gao;Bo Ying;Cheng-Feng Qin-State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,AMMS,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Key laboratory of Jilin Province for Zoonosis Prevention and Control,Changchun,Jilin,China;Beijing Protein and Antibody R&D Engineering Center,Sinocelltech Ltd,Beijing,China
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies:a phase I clinical study
Yongxian Hu;Yali Zhou;Mingming Zhang;Houli Zhao;Guoqing Wei;Wengang Ge;Qu Cui;Qitian Mu;Gong Chen;Lu Han;Tingting Guo;Jiazhen Cui;Xiaoyan Jiang;Xiujun Zheng;Shuhui Yu;Xiaolong Li;Xingwang Zhang;Mingxi Chen;Xiuju Li;Ming Gao;Kang Wang;Cheng Zu;Hao Zhang;Xiaohong He;Yanbin Wang;Dongrui Wang;Jiangtao Ren;He Huang-Bone Marrow Transplantation Center,The First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou,Zhejiang,China;Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou,Zhejiang,China;Institute of Hematology,Zhejiang University,Hangzhou,Zhejiang,China;Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Hangzhou,Zhejiang,China;Nanjing Bioheng Biotech Co.,Ltd,Nanjing,Jiangsu,China;Department of Hematology,Ruian people's Hospital,Wenzhou,Zhejiang,China;Department of Hematology,Beijing Tiantan Hospital,Capital Medical University Beijing China;Laboratory of Stem Cell Transplantation Ningbo First Hospital Ningbo,Zhejiang,China
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Wei Pang;Ying Lu;Yan-Bo Zhao;Fan Shen;Chang-Fa Fan;Qian Wang;Wen-Qiang He;Xiao-Yan He;Ze-Kai Li;Tao-Tao Chen;Cui-Xian Yang;You-Zhi Li;Si-Xuan Xiao;Zu-Jiang Zhao;Xu-Sheng Huang;Rong-Hua Luo;Liu-Meng Yang;Mi Zhang;Xing-Qi Dong;Ming-Hua Li;Xiao-Li Feng;Qing-Cui Zhou;Wang Qu;Shibo Jiang;Songying Ouyang;Yong-Tang Zheng-Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province,KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China;University of the Chinese Academy of Sciences,Beijing,China;The Key Laboratory of Innate Immune Biology of Fujian Province,Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation,Biomedical Research Center of South China,Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education,College of Life Sciences,Fujian Normal University,Fuzhou,Fujian,China;Division of Animal Model Research,Institute for Laboratory Animal Resources,National Institutes for Food and Drug Control,Beijing,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),Shanghai Institute of Infectious Disease and Biosecurity,School of Basic Medical Sciences,Fudan University,Shanghai,China;Yunnan Provincial Infectious Disease Hospital,Kunming,Yunnan,China;Kunming National High-level Biosafety Research Center for Non-human Primates,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。